NSF builds taxpayer-funded biotech labs, then lets companies buy the data
H.R. 7801 — Cloud LAB Act of 2026 · Filed by Jay Obernolte (R-CA) · 4 cosponsors · Introduced Mar 4, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Science Foundation to establish a network of remote-controlled laboratory facilities (cloud labs) equipped with robots and instrumentation to conduct automated biological experiments and generate data for AI training and research. The NSF will fund at least 2 initial labs (Phase II) within 3 years and at least 3 additional labs (Phase III) within 4 years, coordinate with existing public and private labs, and create an advisory board to oversee data access, security, and intellectual property rules. Nonproprietary researchers get free or low-cost access; companies may pay subscription fees for data and infrastructure.
Why we flagged it
The bill's core mechanism is establishing a federally funded network of automated research labs open to academic researchers at no cost, but it explicitly authorizes a commercial subscription model for industry access to publicly generated biological data—a hybrid public-private structure that blurs the boundary between public research investment and private data monetization.
What the text implies
- The bill authorizes NSF to develop a 'payment or subscription model' for industry access to cloud lab infrastructure and data, potentially allowing private companies to profit from biological datasets generated with federal funding while the public research community gets free access—creating a two-tier system where taxpayers subsidize data collection that companies then license.
- The advisory board includes 'industry representatives from different sectors of biotechnology' with discretionary selection by the Director, creating potential conflicts of interest in decisions about data access, intellectual property agreements, and which research priorities get funded.
The full analysis lists 4 implications of this text.
Who stands to gain
biotechnology companies (health, agriculture, chemical production sectors); platform technology providers; cloud infrastructure and robotics vendors